19:30 , Oct 13, 2017 |  BioCentury  |  Product Development

Eyeing complement data

Clinical studies of four complement inhibitors in patients with age-related macular degeneration suggest the best target in the pathway may be complement 3 . However, differences between study populations and methods and durations of treatment...
07:00 , May 26, 2016 |  BC Innovations  |  Product R&D

H is for cancer

Letting the immune system do the heavy work, a group at Duke University has developed a cancer-killing antibody by studying the blood of atypical lung cancer patients with a slowly progressive form of the disease....
08:00 , Dec 10, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: V-set and immunoglobulin domain containing 4 (VSIG4); CD59; complement C5b-9 membrane attack complex (MAC)

Inflammation INDICATION: Shock / trauma In vitro and mouse studies suggest a VSIG4- CD59 fusion protein could help treat traumatic brain injury (TBI). In vitro, dimers of the VSIG4-CD59 fusion protein bound complement 3b (C3b)...
07:00 , Aug 7, 2014 |  BC Innovations  |  Targets & Mechanisms

Adipsin meets beta cells

The long-standing mystery of how adipsin regulates metabolism has been solved by a Harvard-led team that has shown the enzyme can increase insulin secretion by generating the peptide complement 3a . 1 Its therapeutic potential...
07:00 , Jul 9, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Infectious disease Complement 3 (C3) Two separate in vitro studies resolved the crystal structures of C3 components that could be targeted to help treat...
07:00 , Oct 11, 2004 |  BioCentury  |  Product Development

The heart of inflammation

Inflammation is a complex network of interactions that arises in response to tissue injury, regardless of the site or nature of the initiating event. Despite this virtual omnipresence of the inflammatory process throughout the body,...
08:00 , Feb 25, 2002 |  BC Week In Review  |  Clinical News

TP10: Phase II

Interim results of a U.S. placebo-controlled Phase II trial of TP10 given as an infusion in 564 patients undergoing high risk cardiac surgery showed that TP10 failed to meet any of the 4 efficacy endpoints....
08:00 , Feb 25, 2002 |  BioCentury  |  Product Development

Complementary difficulties

The failure of TP10 from Avant Immunotherapeutics Inc. to meet its primary endpoint in a Phase II trial of patients undergoing cardiac surgery is the second such setback for a compound targeting complement in a...
08:00 , Dec 20, 1999 |  BioCentury  |  Emerging Company Profile

EluSys: Seek and destroy

The human immune system is a fairly efficient defense system against foreign antigens, including pathogenic bacteria, viruses and toxins. However, despite its layers of surveillance, the immune system is not perfect. EluSys Therapeutics Inc. hopes...
07:00 , Oct 9, 1995 |  BC Week In Review  |  Clinical News

Alexion preclinical data

Alexion's lead complement inhibitor, 5G1.1-SC, was effective in blocking the complement cascade in an ex vivo model of cardiopulmonary bypass, in which human blood was run through a bypass machine. The results, published in the...